Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis
The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Abstract
Selective serotonin reuptake inhibitors (SSRIs) are frequently used to treat depression during pregnancy and the postpartum period. These drugs are capable of crossing the placenta and being transferred to the newborn during lactation. This report reviews the available information regarding the effects of SSRIs on the fetus and newborn; including long-term neurodevelopmental outcomes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Maternal depression and anxiety are two of the highest reported complications of pregnancy (Lattimore et al. 2005)”
From Pilot early intervention antenatal group program for pregnant women with anxiety and depression (2014) · cites this paper as Lattimore et al. 2005
Citations
Cites
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370 · cited 1×
“The lifetime risk for depression in women varies from 10 to 30%, with peak prevalence during the childbearing years.(1,2) Studies of postpartum depression suggest a 10 to 15% incidence in all parturients, making it one of the most common complications of pregnancy.”
Background(1991) · American Journal of Psychiatry · doi:10.1176/ajp.148.6.705 · Cited by 1,342
Depressive Symptoms among Pregnant Women Screened in Obstetrics Settings
Marcus, S. M., Flynn, H. A., Blow, F. C., & Barry, K. L. (2003) · Journal of Women's Health · doi:10.1089/154099903765448880 · Cited by 742 · cited 1×
“In addition, infants of chronically depressed mothers score inferiorly on the Bayley Mental and Motor Scales, achieve lower growth percentiles at 1 year of age,(4) and have delayed linguistic development and behavioral difficulties.(5) Depressed women have elevated levels norepinephrine and cortisol as markers of stre…”
BackgroundBirth Outcomes in Pregnant Women Taking Fluoxetine
Chambers, C. D., Johnson, K. A., Dick, L. M., Felix, R. J., & Jones, K. L. (1996) · New England Journal of Medicine · doi:10.1056/nejm199610033351402 · Cited by 735
Depression and anxiety in early pregnancy and risk for preeclampsia
Kurki, T. (2000) · Obstetrics & Gynecology · doi:10.1016/s0029-7844(99)00602-x · Cited by 690
Role of selective serotonin reuptake inhibitors in psychiatric disorders: a comprehensive review
Vaswani, M., Linda, F. K., & Ramesh, S. (2003) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/s0278-5846(02)00338-x · Cited by 612 · cited 1×
“This is their major advantage over the tricyclic antidepressants (TCA), and the reason for their increased tolerance and fewer adverse side effects.(12)”
BackgroundNeurodevelopment of Children Exposed in Utero to Antidepressant Drugs
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Gardner, H. A., Theis, J. G. W., Kulin, N., & Koren, G. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360404 · Cited by 573
Field, T. (1995) · Infant Behavior and Development · doi:10.1016/0163-6383(95)90003-9 · Cited by 524
Nulman, I., Rovet, J., Stewart, D. E., Wolpin, J., Pace-Asciak, P., Shuhaiber, S., & Koren, G. (2002) · American Journal of Psychiatry · doi:10.1176/appi.ajp.159.11.1889 · Cited by 441 · cited 4×
“Recently, in a prospective cohort trial, Nulman et al.34,36 evaluated IQ, language development, and temperament in children exposed to TCAs or SSRIs in the first trimester only, and also throughout pregnancy, compared to infants born to mothers who were not depressed and were not exposed to any known teratogenic medic…”
BackgroundResultInfluentialKulin, N. A., Pastuszak, A., Sage, S. R., Schick-Boschetto, B., Spivey, G., Feldkamp, M., Ormond, K., Matsui, D., Stein-Schechman, A. K., Cook, L., et al. (1998) · JAMA · doi:10.1001/jama.279.8.609 · Cited by 424
Research works printed but not linked: 6
- Zeskind PS, Stephens LE . Maternal selective serotonin reuptake inhibitor use during pregnancy and newborn neurobehavior. Pediatrics 2004;113:368–375. · DOI · Paper page
- Costei AM, Kozer E, Ho T, Ito S, Koren G . Perinatal outcome following third trimester exposure to paroxetine. Arch Pediatr Adolesc Med 2002;156:1129–1132. · DOI · Paper page
- Hendrick V, Smith LM, Suri R, et al. Birth outcomes after prenatal exposure to antidepressant medication. Am J Obstet Gynecol 2003;188:812–815. · DOI · Paper page
- Chambers C, Dick LM, Felix RJ, Johnson KA, Jones KL . Pregnancy Outcome in women who use sertraline. Teratology 1999;59:376.
- Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246–2248. · DOI · Paper page
- Zeskind PS, Oberlander TF, Grunau RE, et al. Continuing effects of prenatal SSRI exposure detected by spectral analysis of infant cry sounds at two months of age. Pediatr Res 2005;57:1624A.
Cited by
Donofrio, M. T., Moon-Grady, A. J., Hornberger, L. K., Copel, J. A., Sklansky, M. S., Abuhamad, A., Cuneo, B. F., Huhta, J. C., Jonas, R. A., Krishnan, A., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437597.44550.5d · Cited by 1,275
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
“neonatal adaptation syndrome (PNAS) [1121-1123], while”
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Kennedy, S. H., Lam, R. W., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.043 · Cited by 525
Lam, R. W., Kennedy, S. H., Grigoriadis, S., McIntyre, R. S., Milev, R., Ramasubbu, R., Parikh, S. V., Patten, S. B., & Ravindran, A. V. (2009) · Journal of Affective Disorders · doi:10.1016/j.jad.2009.06.041 · Cited by 431
“, 2006) malformations, but one found evidence that SSRI use late in pregnancy was associated with subtle adverse effects (serotonergic overstimulation, withdrawal syndromes, long term neurobehavioural effects) in newborns (Lattimore et al., 2005).”
Background
Metadata
- Authors
- Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M.
- Affiliations
- University of Michigan (US)
- Venue
- Journal of Perinatology
- Published
- 2005-07-14
- Volume
- 25
- Issue
- 9
- Pages
- 595-604
- ISSN
- 0743-8346 (ISSN-L)
- 1476-5543
- OpenAlex
- W2040155286
- Cited by
- 189
- References
- 55
- Citations by year
- 2026: 5 · 2025: 2 · 2024: 4 · 2023: 3 · 2022: 1 · 2021: 14 · 2020: 6 · 2019: 14 · 2018: 9 · 2017: 13 · 2016: 7 · 2015: 11 · 2014: 11 · 2013: 17 · 2012: 15
- FWCI
- 1.44
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Journal of Perinatology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health
- National Institute of Mental Health (MH065062, R21MH065062, MH068489, R21MH068489)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pediatrics, Perinatology and Child Health › Prenatal Substance Exposure Effects
- Keywords
- selective serotonin reuptake inhibitors, pregnancy, fetal effects, neonatal outcomes, placental transfer, breastfeeding, maternal depression, postpartum depression, neurodevelopmental outcomes, antidepressant safety
- MeSH terms
- Child Development, Female, Fetus, Humans, Infant, Newborn, Maternal-Fetal Exchange, Pregnancy, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis. https://app.cochat.ai/papers/10.1038/sj.jp.7211352
- The paper
- Lattimore, K. A., Donn, S. M., Kaciroti, N., Kemper, A. R., Neal, C. R., & Vazquez, D. M. (2005). Selective Serotonin Reuptake Inhibitor (SSRI) Use during Pregnancy and Effects on the Fetus and Newborn: A Meta-Analysis. Journal of Perinatology. https://doi.org/10.1038/sj.jp.7211352
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.